TABLE 2

The patient’s laboratory test results at time of treatment and follow-up

Test (reference range)	Results at time of therapy^{^a}	Results at follow-up^{^b}
Hemoglobin (12–16 g/dL)	7.1	10.8
Mean corpuscular volume (78–100 fL)	72	77
Red cell distribution width (11.0%–14.0%)	22.6	16.9
Platelet count (150–450 × 10⁹/L)	386	293
Ferritin (11–307 ng/mL)	4.0	11.2
Iron (35–150 μg/dL)	19	28
Total iron binding capacity (225–430 μg/dL)	366	340
Transferrin saturation (20%–55%)	5	8
Aspartate aminotransferase (0–37 U/L)	20	35
Alanine aminotransferase (0–35 U/L)	11	24
Alkaline phosphatase (33–133 U/L)	149	166
Total bilirubin (0–1 mg/dL)	0.9	0.6
Direct bilirubin (0–0.2 mg/dL)	0.1	0.2
Thyroid-stimulating hormone (0.4–5.0 mIU/L)	3.015	2.8

↵^a Select laboratory parameters collected on day bevacizumab therapy was started.
↵^b Select laboratory parameters collected 3 months after bevacizumab therapy was started.